我院2019年1~6月碳青霉烯耐药革兰阴性杆菌分布特点及治疗合理性分析

Abstract
Figure/Table
References (15)
Related Citation (1)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the distribution characteristics and treatment rationality of carbapenem-resistant Gram-negative bacilli(CRO)in our hospital from January to June 2019,and provide evidence for clinical rational use of antibiotics.Methods The data of CROinfection in our hospital from January to June 2019 were retrospectively analyzed,and the results were statistically analyzed.Results A total of 60 CRO strains were detected by our hospital from January to June 2019.The detection rate was 1.43%,mainly carbapenem-resistant Escherichia coli(CREC)5 strains(8.3%),carbapenem-resistant Klebsiella pneumoniae(CRKP)11 strains(18.3%),carbapenem-resistant Pseudomonas aeruginosa(CRPA)14 strains(23.4%),and carbapenem-resistant Acinetobacter baumannii(CRAB)30 strains(50.0%).The CRO specimens were mainly from sputum(56 strains),blood(2 strains),and mid-stage urine(2 strains).CRO was resistant to most antibacterial drugs,and was only sensitive to a few Aminoglycosides,Fluoroquinolones,Minocycline,Compound sinomine,Tigecycline (except Pseudomonas aeruginosa).Conclusion CRO has become an important pathogen in the hospital infection.The supervision of multi-drug resistant bacteria and the rational use of carbapenem antibacterial drugs should be strengthened,and hand hygiene should be paid attention to reduce or avoid the production of multi-drug resistant bacteria.

Key words： Carbapenem-resistant Gram-negative bacilli Distribution characteristics Treatment rationality

Received: 25 October 2019

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEIYun FENG Gui-mei WANG Shu-guang YU Yong-wen▲

Cite this article:

WEIYun FENG Gui-mei WANG Shu-guang YU Yong-wen▲. Distribution characteristics and treatment rationality analysis of carbapenem-resistant Gram-negative bacilli in our hospital from January to June 2019[J]. 中国当代医药, 2020, 27(24): 173-176.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I24/173

[1]	杨丽.医院感染多重耐药菌监测及防控分析[J].检验医学与临床，2019，16（17）：2548-2550.
[2]	胡必杰.中国碳青霉烯耐药革兰阴性杆菌（CRO）感染预防与控制技术指引[J].中华医院感染学杂志，2019，29（13）：2075-2080.
[3]	佘丹阳.不同碳青霉烯类抗生素的区别与临床应用[J].中华结核和呼吸杂志，2008，31（10）：727-728.
[4]	李德雨，何志义.耐碳青霉烯类药物大肠杆菌耐药机制的研究进展[J].临床与病理杂志，2019，39（3）：673-678.
[5]	杨忠慧，钱妙嫤.某院碳青霉烯类抗菌药物不合理使用的原因分析[J].抗感染药学，2019，16（6）：951-954.
[6]	周华，李光辉，陈佰义，等.中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J].中华医学杂志，2014，94（24）：1847-1856.
[7]	李娜，陆阳，郭静.肠杆菌科细菌ESBLs和AmpC酶检测及耐药性分析[J].现代医用影像学，2019，28（2）：431-432.
[8]	周华，周建英，俞云松.多重耐药革兰阴性杆菌感染诊治专家共识解读[J].中华内科杂志，2014，53（12）：984-987.
[9]	中华医学会呼吸病学分会感染学组.铜绿假单胞菌下呼吸道感染诊治专家共识[J].中华结核和呼吸杂志，2014，37（1）：9-15.
[10]	陈佰义，何礼贤，俞云松，等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志，2012，92（2）：76-85.
[11]	苏晓曼，张义，李慧玲.碳青霉烯酶在主动筛查CRKP耐药机制中的作用[J].黑龙江医药科学，2019，42（3）：52-53.
[12]	张侃，马琳，王博，等.耐碳青霉烯肠杆菌科细菌定植与感染研究进展[J].国际呼吸杂志，2019，39（10）：788-792.
[13]	李渊婷，金凤玲.肠杆菌科细菌对碳青霉烯类药物的耐药机制及临床治疗进展[J].中国感染控制杂志，2015，14（9）：644-648.
[14]	弓清梅，宋妤，薛彦，等.重症患者耐碳青霉烯类肺炎克雷伯菌感染的特征及临床危险因素探讨[J].中国药物与临床，2019，19（13）：2196-2198.
[15]	黄勋，邓子德，吴安华，等.多重耐药菌医院感染预防与控制中国专家共识[J].中国感染控制杂志，2015，14（1）：1-9.